Nanotechnology in brain targeting

Katerina Lalatsa, Diana Moreira Leite, Melina Fernandes Figueiredo, Max O'Connor

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review


Patients suffering from malignant brain tumours have an extremely poor prognosis (shorter than 15 months) irrespectively of improvements in surgergy, tumour imaging and therapeutic protocols. Brain tumour treatment has been principally hampered by poor permeability of drugs/therapeutics across the blood-brain barrier (BBB). Nanotechnology enabled treatments have shown unique promise in delivering drugs and macromolecules across the BBB and offer unique abilities in targeting tumour cells exploiting tumour biology, while also improving the pharmacokinetic profile of drugs and reducing off-target side-effects. In this chapter, we focus on the efficacy and safety of developed nano-enabled therapies that are currently under research for the treatment of brain tumours.
Original languageEnglish
Title of host publicationNanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors
EditorsPrashant Kesharwani, Umesh Gupta
Number of pages35
ISBN (Electronic)978-0128122495
ISBN (Print)978-0128122181
Publication statusPublished - 27 Apr 2018


  • Nanomedicines
  • Drug conjugates
  • Dendrimers
  • Nucleic acid-based nanomedicines
  • Peptide-based nanomedicines
  • Polymeric nanoparticles
  • Liposomes
  • Glioblastoma Multiforme
  • Brain tumours


Dive into the research topics of 'Nanotechnology in brain targeting'. Together they form a unique fingerprint.

Cite this